Cargando…

Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial

BACKGROUND: Although great progress has been made over the past 2 years in the scientific understanding of the biology, epidemiology, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), case morbidity and fatality rates remain a great concern and continue to challenge t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pantazopoulos, I., Chalkias, A., Mavrovounis, G., Dimeas, I., Sinis, S., Miziou, A., Rouka, E., Poulas, K., Gourgoulianis, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556252/
https://www.ncbi.nlm.nih.gov/pubmed/36247079
http://dx.doi.org/10.1155/2022/8794127
_version_ 1784807034502250496
author Pantazopoulos, I.
Chalkias, A.
Mavrovounis, G.
Dimeas, I.
Sinis, S.
Miziou, A.
Rouka, E.
Poulas, K.
Gourgoulianis, K.
author_facet Pantazopoulos, I.
Chalkias, A.
Mavrovounis, G.
Dimeas, I.
Sinis, S.
Miziou, A.
Rouka, E.
Poulas, K.
Gourgoulianis, K.
author_sort Pantazopoulos, I.
collection PubMed
description BACKGROUND: Although great progress has been made over the past 2 years in the scientific understanding of the biology, epidemiology, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), case morbidity and fatality rates remain a great concern and continue to challenge the healthcare resources worldwide as novel variants emerge. There is therefore an urgent need for affordable and readily available strategies to reduce viral transmission. Previous studies in non-COVID-19 patients have demonstrated that administration of low-salt (isotonic but 0.0375% Na) and isotonic saline (0.9% Na) solutions has been associated with an immediate, significant reduction in the microbial antigens and a related decline of microbial burden. The aim of the present study was to determine the effect of nasal washes with normal saline 0.9% on nasopharyngeal viral load and outcome in hospitalized patients with COVID-19 pneumonia. METHODS: We performed a prospective, randomized, pilot, controlled trial in 50 patients with confirmed COVID-19 disease. Patients were randomized into two groups, the normal saline group (received normal saline 0.9% solution for nasopharyngeal wash) and the control group (no treatment). In the normal saline group, nasopharyngeal wash was performed every 4 hours for a 16-hour period. Twenty-four hours after the baseline nasopharyngeal swab (and 8 hours after the last wash in the normal saline group), a second nasopharyngeal swab was collected for the semiquantitative estimation of the SARS-CoV-2 viral load as determined by cycle threshold (Ct) values. RESULTS: In the normal saline group, mean N gene Ct values increased significantly 24 hours after the baseline measurement [ΔCt(day2−day1) = 1.87 ± 3.11 cycles, p = 0.007 (95% CI: 0.55 to 3.18)], indicating a decline in SARS-CoV-2 nasopharyngeal viral load by 8.9%. A significant decrease in mean N gene Ct values was observed in the control group, indicating an increase in viral load [ΔCt(day2-day1) = −2.12 ± 2.66, p < 0.001 (95% CI: −3.20 to −1.05)] by 9.7%. The difference between the two groups 24 hours after admission and nasopharyngeal wash was 3.09 cycles (p = 0.005, 95% CI: 0.97 to 5.20). CONCLUSION: Nasal washes with normal saline effectively decreased the viral load during hospitalization and at follow-up.
format Online
Article
Text
id pubmed-9556252
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-95562522022-10-13 Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial Pantazopoulos, I. Chalkias, A. Mavrovounis, G. Dimeas, I. Sinis, S. Miziou, A. Rouka, E. Poulas, K. Gourgoulianis, K. Can Respir J Research Article BACKGROUND: Although great progress has been made over the past 2 years in the scientific understanding of the biology, epidemiology, and pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), case morbidity and fatality rates remain a great concern and continue to challenge the healthcare resources worldwide as novel variants emerge. There is therefore an urgent need for affordable and readily available strategies to reduce viral transmission. Previous studies in non-COVID-19 patients have demonstrated that administration of low-salt (isotonic but 0.0375% Na) and isotonic saline (0.9% Na) solutions has been associated with an immediate, significant reduction in the microbial antigens and a related decline of microbial burden. The aim of the present study was to determine the effect of nasal washes with normal saline 0.9% on nasopharyngeal viral load and outcome in hospitalized patients with COVID-19 pneumonia. METHODS: We performed a prospective, randomized, pilot, controlled trial in 50 patients with confirmed COVID-19 disease. Patients were randomized into two groups, the normal saline group (received normal saline 0.9% solution for nasopharyngeal wash) and the control group (no treatment). In the normal saline group, nasopharyngeal wash was performed every 4 hours for a 16-hour period. Twenty-four hours after the baseline nasopharyngeal swab (and 8 hours after the last wash in the normal saline group), a second nasopharyngeal swab was collected for the semiquantitative estimation of the SARS-CoV-2 viral load as determined by cycle threshold (Ct) values. RESULTS: In the normal saline group, mean N gene Ct values increased significantly 24 hours after the baseline measurement [ΔCt(day2−day1) = 1.87 ± 3.11 cycles, p = 0.007 (95% CI: 0.55 to 3.18)], indicating a decline in SARS-CoV-2 nasopharyngeal viral load by 8.9%. A significant decrease in mean N gene Ct values was observed in the control group, indicating an increase in viral load [ΔCt(day2-day1) = −2.12 ± 2.66, p < 0.001 (95% CI: −3.20 to −1.05)] by 9.7%. The difference between the two groups 24 hours after admission and nasopharyngeal wash was 3.09 cycles (p = 0.005, 95% CI: 0.97 to 5.20). CONCLUSION: Nasal washes with normal saline effectively decreased the viral load during hospitalization and at follow-up. Hindawi 2022-09-27 /pmc/articles/PMC9556252/ /pubmed/36247079 http://dx.doi.org/10.1155/2022/8794127 Text en Copyright © 2022 I. Pantazopoulos et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Pantazopoulos, I.
Chalkias, A.
Mavrovounis, G.
Dimeas, I.
Sinis, S.
Miziou, A.
Rouka, E.
Poulas, K.
Gourgoulianis, K.
Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title_full Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title_fullStr Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title_full_unstemmed Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title_short Nasopharyngeal Wash with Normal Saline Decreases SARS-CoV-2 Viral Load: A Randomized Pilot Controlled Trial
title_sort nasopharyngeal wash with normal saline decreases sars-cov-2 viral load: a randomized pilot controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556252/
https://www.ncbi.nlm.nih.gov/pubmed/36247079
http://dx.doi.org/10.1155/2022/8794127
work_keys_str_mv AT pantazopoulosi nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT chalkiasa nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT mavrovounisg nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT dimeasi nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT siniss nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT mizioua nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT roukae nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT poulask nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial
AT gourgoulianisk nasopharyngealwashwithnormalsalinedecreasessarscov2viralloadarandomizedpilotcontrolledtrial